| 1 |
Montaño J, Garnica J, Santamaria P. Immunomodulatory and immunoregulatory nanomedicines for autoimmunity. Semin Immunol 2021;:101535. [PMID: 34969600 DOI: 10.1016/j.smim.2021.101535] [Reference Citation Analysis]
|
| 2 |
Liu CP, Chen ZD, Ye ZY, He DY, Dang Y, Li ZW, Wang L, Ren M, Fan ZJ, Liu HX. Therapeutic Applications of Functional Nanomaterials for Prostatitis. Front Pharmacol 2021;12:685465. [PMID: 34140892 DOI: 10.3389/fphar.2021.685465] [Reference Citation Analysis]
|
| 3 |
Fu X, He HD, Li CJ, Li N, Jiang SY, Ge HW, Wang R, Wang XL. MicroRNA-155 deficiency attenuates inflammation and oxidative stress in experimental autoimmune prostatitis in a TLR4-dependent manner. Kaohsiung J Med Sci 2020;36:712-20. [PMID: 32436368 DOI: 10.1002/kjm2.12229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Diallo MT, Ali M, Zhang Q, Wang Y, Long Z, Ding J, Zhang C, Zhu X, Jiang M, Sun Q, Zhou X, Wang D. Morphological study of chronic prostatitis-chronic pelvic pain syndrome (CP/CPPS) normal modeling dose of T2 peptide in mice. Int Urol Nephrol 2022. [PMID: 35438412 DOI: 10.1007/s11255-022-03185-6] [Reference Citation Analysis]
|
| 5 |
Appiya Santharam M, Khan FU, Naveed M, Ali U, Ahsan MZ, Khongorzul P, Shoaib RM, Ihsan AU. Interventions to chronic prostatitis/Chronic pelvic pain syndrome treatment. Where are we standing and what's next? Eur J Pharmacol 2019;857:172429. [PMID: 31170381 DOI: 10.1016/j.ejphar.2019.172429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Shandilya R, Pathak N, Lohiya NK, Sharma RS, Mishra PK. Nanotechnology in reproductive medicine: Opportunities for clinical translation. Clin Exp Reprod Med 2020;47:245-62. [PMID: 33227186 DOI: 10.5653/cerm.2020.03650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Liu Y, Wazir J, Tang M, Ullah R, Chen Y, Chen T, Zhou X. Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy. Int Urol Nephrol 2021;53:607-18. [PMID: 33200334 DOI: 10.1007/s11255-020-02703-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Liu Y, Mikrani R, Xie D, Wazir J, Shrestha S, Ullah R, Baig MMFA, Ahmed A, Srivastava PK, Thapa KB, Zhou X. Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines. Fundam Clin Pharmacol 2020;34:160-72. [DOI: 10.1111/fcp.12517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Liu Y, Tang M, Zhang Q, Li C, Lv R, Min H, Zhou X. T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis. Inflammation 2021;44:243-8. [PMID: 32827084 DOI: 10.1007/s10753-020-01326-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
